Financial Performance - Operating revenue for the first nine months of 2022 was RMB 788,255,408.91, representing a year-on-year growth of 15.04%[15] - Net profit attributable to shareholders for the first nine months of 2022 was RMB 66,535,371.20, up 7.88% from the same period last year[15] - In Q3 2022, operating revenue was RMB 307,912,933.54, a significant increase of 49.06% compared to Q3 2021[16] - The net profit attributable to shareholders in Q3 2022 was RMB 23,405,523.46, reflecting a growth of 27.70% year-on-year[16] - Net profit for the year 2022 reached CNY 66,535,371.20, an increase of 8.5% compared to CNY 61,673,591.54 in 2021[46] - Total revenue for the first nine months of 2022 was CNY 666,187,427.20, up 19.4% from CNY 558,428,571.99 in the same period of 2021[49] - Operating profit for the year 2022 was CNY 64,328,232.87, representing a 31.2% increase from CNY 49,009,249.88 in 2021[50] - Operating profit for Q3 2022 was ¥27.49 million, compared to ¥22.11 million in Q3 2021, indicating a growth of 24.5%[45] Cash Flow - The net cash flow from operating activities for the first nine months of 2022 was -RMB 178,527,056.21, a decline of 172.87% compared to the previous year[15] - Operating cash inflow for the first nine months of 2022 was CNY 607,884,791.77, a decrease of 6.1% compared to CNY 647,286,390.53 in the same period of 2021[52] - Total cash outflow from operating activities increased to CNY 786,411,847.98, up 10.3% from CNY 712,711,951.83 year-on-year[52] - Investment cash inflow totaled CNY 200,364,962.21, significantly higher than CNY 128,240.00 in the same period last year[53] - Net cash flow from investment activities improved to CNY 83,592,586.99, compared to a negative CNY 12,598,294.56 in the previous year[53] - Cash inflow from financing activities was CNY 60,881,378.40, an increase from CNY 45,956,602.69 year-on-year[53] - Net cash flow from financing activities rose to CNY 29,128,939.75, compared to CNY 1,515,776.92 in the same period last year[53] - The ending cash and cash equivalents balance was CNY 53,066,729.76, up from CNY 27,718,205.47 in the previous year[53] - The company reported a net cash decrease of CNY 65,613,241.68 for the period, an improvement from a decrease of CNY 76,520,170.33 in the previous year[53] Assets and Liabilities - Total assets as of September 30, 2022, reached RMB 1,226,985,692.61, an increase of 11.00% compared to the end of the previous year[15] - Total liabilities rose to CNY 338,978,733.32, compared to CNY 257,065,210.47 in the previous year, indicating an increase of about 31.8%[38] - The company’s equity attributable to shareholders reached CNY 888,006,959.29, up from CNY 848,376,588.09 in the previous year[38] - Accounts receivable increased to CNY 494,152,324.55 from CNY 366,525,496.75 year-over-year, reflecting a growth of approximately 34.8%[36] - The company reported a total of CNY 21,094,599.22 in assets under restriction, accounting for 1.72% of total assets[32] - Total assets as of September 30, 2022, amounted to ¥1,178.56 million, an increase from ¥994.82 million at the end of 2021, representing an 18.5% growth[42] - Total liabilities as of September 30, 2022, were ¥342.72 million, compared to ¥188.08 million at the end of 2021, showing an increase of 82.2%[42] Shareholder Information - The total number of ordinary shares at the end of the reporting period was 107,620,000, with 45.26% being unrestricted shares[23] - The largest shareholder, Zhao Dongming, holds 42,143,334 shares, representing 39.16% of the total shares[25] - The second-largest shareholder, Jiang Xueyuan, holds 10,648,016 shares, accounting for 9.89% of the total shares[25] - The total number of restricted shares is 58,907,750, which constitutes 54.74% of the total shares[24] - The company has 9,861 ordinary shareholders at the end of the reporting period[24] Expenses and Gains - The company's financial expenses decreased by 87.53% compared to the previous period, mainly due to increased interest income and exchange gains[18] - Research and development expenses for Q3 2022 were ¥11.05 million, significantly higher than ¥5.98 million in Q3 2021, representing an 84.5% increase[45] - Research and development expenses for the first nine months of 2022 totaled CNY 16,722,234.18, an increase of 17.9% compared to CNY 14,174,405.50 in 2021[49] - The company reported a reversal of impairment provisions for receivables amounting to CNY 2,951,493.04[21] - Government subsidies recognized in the current period amounted to CNY 1,883,037.83[21] - The company incurred a credit impairment loss of CNY 2,608,716.54 in the first nine months of 2022, compared to a gain of CNY 2,508,659.26 in the same period of 2021[50] Other Information - There are no significant changes in accounting policies or errors corrected during the reporting period[22] - The company has no preferred stock outstanding as of the reporting period[27] - The company has no ongoing litigation or arbitration matters during the reporting period[30] - There were no significant related party transactions or external borrowings reported during the period[30] - The company has fulfilled all disclosed commitments without any overdue obligations[30]
禾昌聚合(832089) - 2022 Q3 - 季度财报